{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:42:51Z","timestamp":1784875371500,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The blockade of the renin\u2013angiotensin\u2013aldosterone system (RAAS) by angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) is one of the most common treatments for hypertension, heart failure and renal diseases. However, concerns have been raised about a possible link between RAAS-blockers and an increased risk of cancer, particularly of lung cancer. This narrative review aims to give a critical appraisal of current evidence and to help physicians understand potential links between RAAS blockade and de novo lung cancer development.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Numerous pharmaco-epidemiologic studies, mostly retrospective cohort analyses, evaluated the association of RAAS blockade with lung cancer incidence and reported inconsistent findings. Meta-analyses could not further clarify a possible link between RAAS blockade and the risk of lung cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>International regulatory agencies (FDA, EMA) have concluded that the use of RAAS blockers is not associated with an increased risk of developing lung cancer. Co-administration of RAAS blockers to systemic therapy of advanced non-small cell lung cancer seems to have positive effects on the outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Until more comprehensive analyses have been completed, there is no need to change clinical practise. Additional prospective randomized trials with long-term follow-up are needed to investigate the effects of these drugs on the development and progression of lung cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-020-03445-x","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T13:03:01Z","timestamp":1606222981000},"page":"195-204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Risk of lung cancer and renin\u2013angiotensin blockade: a concise review"],"prefix":"10.1007","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3227-3105","authenticated-orcid":false,"given":"Tobias","family":"Rachow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0604-6109","authenticated-orcid":false,"given":"Helmut","family":"Schiffl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1332-9879","authenticated-orcid":false,"given":"Susanne M.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"3445_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1182\/blood-2003-08-2974","volume":"104","author":"A Alvarez","year":"2004","unstructured":"Alvarez A et al (2004) Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood 104:402\u2013408. https:\/\/doi.org\/10.1182\/blood-2003-08-2974","journal-title":"Blood"},{"key":"3445_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/sj.bjc.6604431","volume":"99","author":"O Arrieta","year":"2008","unstructured":"Arrieta O et al (2008) Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis. Br J Cancer 99:160\u2013166. https:\/\/doi.org\/10.1038\/sj.bjc.6604431","journal-title":"Br J Cancer"},{"key":"3445_CR3","doi-asserted-by":"publisher","first-page":"e887","DOI":"10.1097\/MD.0000000000000887","volume":"94","author":"A Aydiner","year":"2015","unstructured":"Aydiner A, Ciftci R, Sen F (2015) Renin-Angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib. Medicine (Baltimore) 94:e887. https:\/\/doi.org\/10.1097\/MD.0000000000000887","journal-title":"Medicine (Baltimore)"},{"key":"3445_CR4","doi-asserted-by":"publisher","first-page":"e50893","DOI":"10.1371\/journal.pone.0050893","volume":"7","author":"L Azoulay","year":"2012","unstructured":"Azoulay L, Assimes TL, Yin H, Bartels DB, Schiffrin EL, Suissa S (2012) Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS ONE 7:e50893. https:\/\/doi.org\/10.1371\/journal.pone.0050893","journal-title":"PLoS ONE"},{"key":"3445_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s1470-2045(10)70260-6","volume":"12","author":"S Bangalore","year":"2011","unstructured":"Bangalore S et al (2011) Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 12:65\u201382. https:\/\/doi.org\/10.1016\/s1470-2045(10)70260-6","journal-title":"Lancet Oncol"},{"key":"3445_CR6","doi-asserted-by":"publisher","first-page":"e2697","DOI":"10.1136\/bmj.e2697","volume":"344","author":"K Bhaskaran","year":"2012","unstructured":"Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L (2012) Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ 344:e2697. https:\/\/doi.org\/10.1136\/bmj.e2697","journal-title":"BMJ"},{"key":"3445_CR7","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/JCO.2011.35.1908","volume":"29","author":"CH Chang","year":"2011","unstructured":"Chang CH, Lin JW, Wu LC, Lai MS (2011) Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol 29:3001\u20133007. https:\/\/doi.org\/10.1200\/JCO.2011.35.1908","journal-title":"J Clin Oncol"},{"key":"3445_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/jch.12228","volume":"16","author":"YY Chiang","year":"2014","unstructured":"Chiang YY, Chen KB, Tsai TH, Tsai WC (2014) Lowered cancer risk with ACE inhibitors\/ARBs: a population-based cohort study. J Clin Hypertens (Greenwich) 16:27\u201333. https:\/\/doi.org\/10.1111\/jch.12228","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"3445_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","volume":"29","author":"ARBT Collaboration","year":"2011","unstructured":"Collaboration ARBT (2011) Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens 29:623\u2013635. https:\/\/doi.org\/10.1097\/HJH.0b013e328344a7de","journal-title":"J Hypertens"},{"key":"3445_CR10","doi-asserted-by":"publisher","first-page":"k4337","DOI":"10.1136\/bmj.k4337","volume":"363","author":"D Cronin-Fenton","year":"2018","unstructured":"Cronin-Fenton D (2018) Angiotensin converting enzyme inhibitors and lung cancer. BMJ 363:k4337. https:\/\/doi.org\/10.1136\/bmj.k4337","journal-title":"BMJ"},{"key":"3445_CR11","doi-asserted-by":"publisher","first-page":"e0226553","DOI":"10.1371\/journal.pone.0226553","volume":"14","author":"SM Danilov","year":"2019","unstructured":"Danilov SM, Metzger R, Klieser E, Sotlar K, Trakht IN, Garcia JGN (2019) Tissue ACE phenotyping in lung cancer. PLoS ONE 14:e0226553. https:\/\/doi.org\/10.1371\/journal.pone.0226553","journal-title":"PLoS ONE"},{"key":"3445_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2019.04.019","volume":"64","author":"T Datzmann","year":"2019","unstructured":"Datzmann T, Fuchs S, Andree D, Hohenstein B, Schmitt J, Schindler C (2019) Systematic review and meta-analysis of randomised controlled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer. Eur J Intern Med 64:1\u20139. https:\/\/doi.org\/10.1016\/j.ejim.2019.04.019","journal-title":"Eur J Intern Med"},{"key":"3445_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1172\/jci16645","volume":"112","author":"K Egami","year":"2003","unstructured":"Egami K et al (2003) Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112:67\u201375. https:\/\/doi.org\/10.1172\/jci16645","journal-title":"J Clin Invest"},{"key":"3445_CR14","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3892\/or.2011.1394","volume":"26","author":"Y Feng","year":"2011","unstructured":"Feng Y et al (2011) Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro. Oncol Rep 26:1157\u20131164. https:\/\/doi.org\/10.3892\/or.2011.1394","journal-title":"Oncol Rep"},{"key":"3445_CR15","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1002\/1097-0142(20011101)92:9<2462::aid-cncr1596>3.0.co;2-l","volume":"92","author":"S Friis","year":"2001","unstructured":"Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, Olsen JH (2001) Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92:2462\u20132470. https:\/\/doi.org\/10.1002\/1097-0142(20011101)92:9%3c2462::aid-cncr1596%3e3.0.co;2-l","journal-title":"Cancer"},{"key":"3445_CR16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrc2945","volume":"10","author":"AJ George","year":"2010","unstructured":"George AJ, Thomas WG, Hannan RD (2010) The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 10:745\u2013759. https:\/\/doi.org\/10.1038\/nrc2945","journal-title":"Nat Rev Cancer"},{"key":"3445_CR17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/pds.3977","volume":"25","author":"M Gokhale","year":"2016","unstructured":"Gokhale M, Girman C, Chen Y, Pate V, Funk MJ, Sturmer T (2016) Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf 25:512\u2013520. https:\/\/doi.org\/10.1002\/pds.3977","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3445_CR18","doi-asserted-by":"publisher","first-page":"6914976","DOI":"10.1155\/2017\/6914976","volume":"2017","author":"B Goldstein","year":"2017","unstructured":"Goldstein B, Trivedi M, Speth RC (2017) Alterations in gene expression of components of the renin-angiotensin system and its related enzymes in lung cancer. Lung Cancer Int 2017:6914976. https:\/\/doi.org\/10.1155\/2017\/6914976","journal-title":"Lung Cancer Int"},{"key":"3445_CR19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/jcp.10313","volume":"196","author":"S Greco","year":"2003","unstructured":"Greco S et al (2003) Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol 196:370\u2013377. https:\/\/doi.org\/10.1002\/jcp.10313","journal-title":"J Cell Physiol"},{"key":"3445_CR20","doi-asserted-by":"publisher","first-page":"k4209","DOI":"10.1136\/bmj.k4209","volume":"363","author":"BM Hicks","year":"2018","unstructured":"Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L (2018) Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ 363:k4209. https:\/\/doi.org\/10.1136\/bmj.k4209","journal-title":"BMJ"},{"key":"3445_CR21","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.amjcard.2010.11.026","volume":"107","author":"CC Huang","year":"2011","unstructured":"Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ, Chen JW, Leu HB (2011) Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol 107:1028\u20131033. https:\/\/doi.org\/10.1016\/j.amjcard.2010.11.026","journal-title":"Am J Cardiol"},{"key":"3445_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bcp.2018.03.008","volume":"151","author":"S Ishikane","year":"2018","unstructured":"Ishikane S, Takahashi-Yanaga F (2018) The role of angiotensin II in cancer metastasis: potential of renin-angiotensin system blockade as a treatment for cancer metastasis. Biochem Pharmacol 151:96\u2013103. https:\/\/doi.org\/10.1016\/j.bcp.2018.03.008","journal-title":"Biochem Pharmacol"},{"key":"3445_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/s0140-6736(98)03228-0","volume":"352","author":"AF Lever","year":"1998","unstructured":"Lever AF et al (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352:179\u2013184. https:\/\/doi.org\/10.1016\/s0140-6736(98)03228-0","journal-title":"Lancet"},{"key":"3445_CR24","doi-asserted-by":"publisher","first-page":"e37396","DOI":"10.1371\/journal.pone.0037396","volume":"7","author":"YF Li","year":"2012","unstructured":"Li YF et al (2012) Angiotensin-converting enzyme (ACE) gene insertion\/deletion polymorphism and ACE inhibitor-related cough: a meta-analysis. PLoS ONE 7:e37396. https:\/\/doi.org\/10.1371\/journal.pone.0037396","journal-title":"PLoS ONE"},{"key":"3445_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030747","author":"SY Lin","year":"2020","unstructured":"Lin SY et al (2020) Association between angiotensin-converting enzyme inhibitors and lung cancer-a nationwide, population-based, propensity score-matched cohort study. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12030747","journal-title":"Cancers (Basel)"},{"issue":"189\u2013197","key":"3445_CR26","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/j.cllc.2016.07.008","volume":"18","author":"AR Menter","year":"2017","unstructured":"Menter AR et al (2017) Effect of angiotensin system inhibitors on survival in patients receiving chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 18(189\u2013197):e183. https:\/\/doi.org\/10.1016\/j.cllc.2016.07.008","journal-title":"Clin Lung Cancer"},{"key":"3445_CR27","doi-asserted-by":"publisher","first-page":"21359","DOI":"10.1038\/srep21359","volume":"6","author":"L Miao","year":"2016","unstructured":"Miao L, Chen W, Zhou L, Wan H, Gao B, Feng Y (2016) Impact of angiotensin I-converting enzyme inhibitors and angiotensin II type-1 receptor blockers on survival of patients with NSCLC. Sci Rep 6:21359. https:\/\/doi.org\/10.1038\/srep21359","journal-title":"Sci Rep"},{"key":"3445_CR28","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1161\/circulationaha.110.007336","volume":"123","author":"B Pasternak","year":"2011","unstructured":"Pasternak B, Svanstrom H, Callreus T, Melbye M, Hviid A (2011) Use of angiotensin receptor blockers and the risk of cancer. Circulation 123:1729\u20131736. https:\/\/doi.org\/10.1161\/circulationaha.110.007336","journal-title":"Circulation"},{"key":"3445_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13046-017-0542-0","volume":"36","author":"N Pei","year":"2017","unstructured":"Pei N et al (2017) Angiotensin II type 2 receptor promotes apoptosis and inhibits angiogenesis in bladder cancer. J Exp Clin Cancer Res 36:77. https:\/\/doi.org\/10.1186\/s13046-017-0542-0","journal-title":"J Exp Clin Cancer Res"},{"key":"3445_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5616","author":"M Pinter","year":"2017","unstructured":"Pinter M, Jain RK (2017) Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aan5616","journal-title":"Sci Transl Med"},{"key":"3445_CR31","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1097\/HJH.0b013e3283621ea3","volume":"31","author":"GA Rao","year":"2013","unstructured":"Rao GA et al (2013) Angiotensin receptor blockers: are they related to lung cancer? J Hypertens 31:1669\u20131675. https:\/\/doi.org\/10.1097\/HJH.0b013e3283621ea3","journal-title":"J Hypertens"},{"key":"3445_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/bjc.1981.21","volume":"43","author":"FK Romer","year":"1981","unstructured":"Romer FK (1981) Angiotensin-converting enzyme and its association with outcome in lung cancer. Br J Cancer 43:135\u2013142. https:\/\/doi.org\/10.1038\/bjc.1981.21","journal-title":"Br J Cancer"},{"key":"3445_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nrm1312","volume":"5","author":"B Sedgwick","year":"2004","unstructured":"Sedgwick B (2004) Repairing DNA-methylation damage. Nat Rev Mol Cell Biol 5:148\u2013157. https:\/\/doi.org\/10.1038\/nrm1312","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3445_CR34","doi-asserted-by":"publisher","first-page":"1009.e1019","DOI":"10.1016\/j.urology.2010.11.002","volume":"77","author":"S Shirotake","year":"2011","unstructured":"Shirotake S, Miyajima A, Kosaka T, Tanaka N, Maeda T, Kikuchi E, Oya M (2011) Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. Urology 77:1009.e1019-1025. https:\/\/doi.org\/10.1016\/j.urology.2010.11.002","journal-title":"Urology"},{"key":"3445_CR35","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/s1470-2045(10)70106-6","volume":"11","author":"I Sipahi","year":"2010","unstructured":"Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (2010) Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 11:627\u2013636. https:\/\/doi.org\/10.1016\/s1470-2045(10)70106-6","journal-title":"Lancet Oncol"},{"key":"3445_CR36","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/s1357-2725(02)00271-6","volume":"35","author":"Y Suzuki","year":"2003","unstructured":"Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J (2003) Inflammation and angiotensin II. Int J Biochem Cell Biol 35:881\u2013900. https:\/\/doi.org\/10.1016\/s1357-2725(02)00271-6","journal-title":"Int J Biochem Cell Biol"},{"key":"3445_CR37","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/ajh\/hpw095","volume":"29","author":"K Tascilar","year":"2016","unstructured":"Tascilar K, Azoulay L, Dell\u2019Aniello S, Bartels DB, Suissa S (2016) The use of telmisartan and the incidence of cancer. Am J Hypertens 29:1358\u20131365. https:\/\/doi.org\/10.1093\/ajh\/hpw095","journal-title":"Am J Hypertens"},{"key":"3445_CR38","first-page":"4789","volume":"35","author":"S Tawinwung","year":"2015","unstructured":"Tawinwung S, Ninsontia C, Chanvorachote P (2015) Angiotensin II increases cancer stem cell-like phenotype in lung cancer cells. Anticancer Res 35:4789\u20134797","journal-title":"Anticancer Res"},{"key":"3445_CR39","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/s0735-1097(99)00594-x","volume":"35","author":"T Tsutamoto","year":"2000","unstructured":"Tsutamoto T et al (2000) Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 35:714\u2013721. https:\/\/doi.org\/10.1016\/s0735-1097(99)00594-x","journal-title":"J Am Coll Cardiol"},{"key":"3445_CR40","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD (2020) Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 382:1653\u20131659. https:\/\/doi.org\/10.1056\/NEJMsr2005760","journal-title":"N Engl J Med"},{"key":"3445_CR41","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1159\/000227224","volume":"50","author":"AS Varela","year":"1993","unstructured":"Varela AS, Bosco Lopez Saez JJ (1993) Utility of serum activity of angiotensin-converting enzyme as a tumor marker. Oncology 50:430\u2013435. https:\/\/doi.org\/10.1159\/000227224","journal-title":"Oncology"},{"key":"3445_CR42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.35841\/medical-research.1.1.28-34","volume":"1","author":"N Wang","year":"2017","unstructured":"Wang N, Liu J, Wang W, Qin J, Lin D (2017) The impact of Renin-angiotensin system blockers on lung cancers prognosis: a prisma-compliant systematic review and meta-analysis. Allied J Med Res 1:28\u201334","journal-title":"Allied J Med Res"},{"key":"3445_CR43","doi-asserted-by":"publisher","first-page":"e8188","DOI":"10.7717\/peerj.8188","volume":"7","author":"J Wei","year":"2019","unstructured":"Wei J et al (2019) Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension. PeerJ 7:e8188. https:\/\/doi.org\/10.7717\/peerj.8188","journal-title":"PeerJ"},{"key":"3445_CR44","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00432-009-0587-3","volume":"135","author":"S Wilop","year":"2009","unstructured":"Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E (2009) Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 135:1429\u20131435. https:\/\/doi.org\/10.1007\/s00432-009-0587-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"3445_CR45","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan T, Rindtorff N, Boutros M (2017) Wnt signaling in cancer. Oncogene 36:1461\u20131473. https:\/\/doi.org\/10.1038\/onc.2016.304","journal-title":"Oncogene"},{"key":"3445_CR46","first-page":"12656","volume":"8","author":"J Zhang","year":"2015","unstructured":"Zhang J et al (2015) Angiotensin receptor blockers (ARBs) reduce the risk of lung cancer: a systematic review and meta-analysis. Int J Clin Exp Med 8:12656\u201312660","journal-title":"Int J Clin Exp Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03445-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-020-03445-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03445-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T20:27:47Z","timestamp":1610742467000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-020-03445-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["3445"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03445-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"6 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}